Advertisement

Tumor Biology

, Volume 33, Issue 1, pp 247–255 | Cite as

IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells

  • Lei Cui
  • Yuezhen Deng
  • Yefei Rong
  • Wenhui Lou
  • Zhengfa Mao
  • Yuanyuan Feng
  • Dong Xie
  • Dayong Jin
Research Article

Abstract

Pancreatic cancer is one of the most malignant diseases in the world. Interferon regulator factor 2 (IRF-2), an interferon regulatory factor, has been known to act as an oncogene in distinct types of cancer. In this study, we found that the expression of IRF-2 was up-regulated in primary pancreatic cancer samples and associated with tumor size, differentiation, tumor–node–metastasis stage, and survival of the patients. In pancreatic cancer cells, knockdown on the expression of IRF-2 inhibited cell growth in the liquid culture and on the soft agar. Mechanistically, IRF-2 modulated the growth of pancreatic cancer cells through regulating proliferation and apoptosis effectors, such as cyclin D1 and BAX. Collectively, these results suggest that IRF-2 plays an important role in the tumorigenesis of pancreatic cancer and down-regulation of IRF-2 would be a new treatment target for pancreatic cancer.

Keywords

IRF-2 Pancreatic cancer Tissue array Cell growth and apoptosis 

Notes

Acknowledgments

The authors gratefully thank the scholarship of SA-SIBS. This project is supported by China Postdoctoral Science Foundation (20100480636) to Yuezhen Deng.

Conflicts of interest

None

Supplementary material

13277_2011_273_Fig5_ESM.jpg (85 kb)
Fig. S1

Knockdown on the expression of IRF-2 did not affect cell migration. A Si con, si 1#, and si 2# MIAPaCa-2 cells were tested with the Boyden Chamber assay. After 15 h, cells that migrated through the filter membrane of the Boyden chamber were stained, and representative results are shown in the upper panel. B Quantification of migratory cells was analyzed with Image Pro software and is shown in the basal panel. (JPEG 85 kb)

13277_2011_273_MOESM1_ESM.tif (24.9 mb)
High resolution image (TIFF 25505 kb)
13277_2011_273_Fig6_ESM.jpg (38 kb)
Fig. S2

Down-regulation of IRF-1 and IRF-3 in pancreatic cancer. A Relative expression of IRF-1 mRNA in 30 pancreatic cancer tissues compared to the paired normal tissues. B Relative expression of IRF-3 mRNA in 30 pancreatic cancer tissues compared to the paired normal tissues. (JPEG 37 kb)

13277_2011_273_MOESM2_ESM.tif (13.9 mb)
High resolution image (TIFF 14208 kb)

References

  1. 1.
    Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;316:455–65.CrossRefGoogle Scholar
  2. 2.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 1992;362:1605–17.CrossRefGoogle Scholar
  3. 3.
    Maiello E. A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma. Clin Ter. 1998;149:351–5.PubMedGoogle Scholar
  4. 4.
    Holzman DC. Pancreatic cancer: will incremental advances begin to make a difference? J Natl Cancer Inst. 1996;102:1821–3.Google Scholar
  5. 5.
    Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol. 2010;8:71–3.CrossRefGoogle Scholar
  6. 6.
    Milandri C, et al. Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience. Hepatogastroenterology. 2007;54:2373–7.PubMedGoogle Scholar
  7. 7.
    Hruban RH, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969–72.PubMedGoogle Scholar
  8. 8.
    Garcea G, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancern. 2005;41:2213–36.CrossRefGoogle Scholar
  9. 9.
    Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol. 2007;13:4423–30.PubMedGoogle Scholar
  10. 10.
    Ghiorzo P, et al. INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol. 2004;15:70–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Naccarati A, et al. Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. Carcinogenesis. 2009;30:666–70.Google Scholar
  12. 12.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Harada H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie. 1998;80:641–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Watanabe N, Taniguchi T. Involvement of positive (IRF-1) and negative (IRF-2) transcription factors in the gene regulation of the type I interferon system. Tanpakushitsu Kakusan Koso. 1992;37:2813–22.PubMedGoogle Scholar
  15. 15.
    Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997;8:293–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Harada H, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science. 1993;259:971–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Xi H, et al. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 1999;18:5889–903.PubMedCrossRefGoogle Scholar
  18. 18.
    Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc Natl Acad Sci USA. 1993;90:5893–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Taniguchi T. Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J Cell Physiol. 1997;173:128–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Choo A, et al. siRNA targeting the IRF-2 transcription factor inhibits leukaemic cell growth. Int J Oncol. 2008;32:175–83.Google Scholar
  21. 21.
    Choo A, et al. The role of IRF-1 and IRF-2 transcription factors in leukaemogenesis. Curr Gene Ther. 2006;6:543–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Doherty GM, et al. Interferon regulatory factor expression in human breast cancer. Ann Surg. 2001;232:623–9.CrossRefGoogle Scholar
  23. 23.
    Connett JM, et al. Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays. J Interferon Cytokine Res. 2005;25:587–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17:315–37.CrossRefGoogle Scholar
  25. 25.
    Wang Y, et al. Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res. 2008;68:1136–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang Y, et al. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res. 2007;67:2535–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. Int J Cancer. 2000;87:803–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Stanger BZ, Dor Y. Dissecting the cellular origins of pancreatic cancer. Cell Cycle. 2006;5:43–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Chung DC. Cyclin D1 in human neuroendocrine: tumorigenesis. Ann NY Acad Sci. 2004;1014:209–17.PubMedCrossRefGoogle Scholar
  31. 31.
    Gao J, et al. IRF-1 transcriptionally up-regulates PUMA which mediates the mitochondrial apoptotic pathway in IRF-1 induced apoptosis in cancer cells. Cell Death Differ. 2010;17:699–709.PubMedCrossRefGoogle Scholar
  32. 32.
    Kim EJ, et al. Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem. 2002;85:369–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Hamacher R, et al. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008;7:64.PubMedCrossRefGoogle Scholar
  34. 34.
    Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer. 2003;2:6.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • Lei Cui
    • 1
  • Yuezhen Deng
    • 2
  • Yefei Rong
    • 1
  • Wenhui Lou
    • 1
  • Zhengfa Mao
    • 1
  • Yuanyuan Feng
    • 2
  • Dong Xie
    • 2
  • Dayong Jin
    • 1
  1. 1.General Surgery Department, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Institute for Nutritional Sciences, Shanghai Institutes for Biological SciencesChinese Academy of SciencesShanghaiChina

Personalised recommendations